4
Changes in Ownership
NewAmsterdam Pharma Co N.V. Filed Acc 0001193125-26-019686
Chief Financial Officer sold 100,000 shares at an average $32.61 ($3,260,618)
- Chief Financial Officer acquired 100,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Somaiya Mayur Ian · Chief Financial Officer
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-20 | Exercise or conversion : show line 1 in the form 10b5-1 | +60,216 | $9.26 | $557,600 | 118,598 | D |
| 2026-01-20 | Sale : show line 2 in the form 10b5-1 | −900 | $30.64 | $27,576 | 117,698 | D |
| 2026-01-20 | Sale : show line 3 in the form 10b5-1 | −39,712 | $31.78 | $1,262,047 | 77,986 | D |
| 2026-01-20 | Sale : show line 4 in the form 10b5-1 | −19,604 | $32.38 | $634,778 | 58,382 | D |
| 2026-01-21 | Exercise or conversion : show line 5 in the form 10b5-1 | +39,784 | $9.26 | $368,400 | 98,166 | D |
| 2026-01-21 | Sale : show line 6 in the form 10b5-1 | −15,422 | $33.25 | $512,782 | 82,744 | D |
| 2026-01-21 | Sale : show line 7 in the form 10b5-1 | −24,362 | $33.80 | $823,436 | 58,382 | D |
| Open-market sales · 100,000 sh · avg $32.61 · $3,260,618 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-20 | Exercise or conversion : show line 8 in the form 10b5-1 Option (Right to Buy) | −60,216 | 702,598 | D |
| 2026-01-21 | Exercise or conversion : show line 9 in the form 10b5-1 Option (Right to Buy) | −39,784 | 662,814 | D |
Loading xslF345X05/ownership.xml…